This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Formiga, F. Articles by Moga, I. Search for Related Content PubMed PubMed Citation Articles by Formiga, F. Articles by Moga, I. Social Bookmarking                   What's this?

Bone mineral density and hormonal status in men with systemic lupus erythematosus

Internal Medicine, c/Feixa Llarga s/n., Hospital de Bellvitg Princeps d'Espanya

JM Nolla

Rheumatology, c/Feixa Llarga s/n., Hospital de Bellvitg Princeps d'Espanya

F. Mitjavila

Internal Medicine, c/Feixa Llarga s/n., Hospital de Bellvitg Princeps d'Espanya

R. Bonnin

Hormone Unit, Internal Medicine Service, c/Feixa Llarga s/n., Hospital de Bellvitge Princeps d'Espanya, L'Hospitalet de Llobregat, Barcelona, Spain

MA Navarro

Hormone Unit, Internal Medicine Service, c/Feixa Llarga s/n., Hospital de Bellvitge Princeps d'Espanya, L'Hospitalet de Llobregat, Barcelona, Spain

I. Moga

Internal Medicine, c/Feixa Llarga s/n., Hospital de Bellvitg Princeps d'Espanya

A loss in bone mass was reported in premenopausal systemic lupus erythematosus (SLE) women, but this problem has not been studied in SLE males. We evaluated bone mineral density (BMD) in SLE males and the relationship between prolactin (PRL) and testosterone with BMD. We also studied the controversial effect of steroid therapy on BMD in these patients. We measured BMD in the lumbar spine and at the hip in 20 SLE men (mean age 37 y) and in the controls (n = 40). We measured PRL and testosterone in serum and saliva. The mean dose of prednisone at the time of study was 11.6 mg; and cumulative dose was 17.6 g. No significative decrease in BMD was detected in SLE males vs controls; either in the lumbar spine (1.00 ± 0.1 vs 1.05 ± 0.1 g/cm²) or in the femoral neck (0.84 ± 0.1 vs 0.87 ± 0.1 g/cm²). No patient or control had osteoporosis or fractures. We did not find any relationship between BMD and cumulative dose and baseline dose of corticosteroids. The mean values of PRL and testosterone (serum and salivary) were in the normal range. We did not find any correlation between BMD, PRL and androgens. This study did not show a loss in bone mass in SLE men on corticosteroid therapy.

Key Words: systemic lupus erythematosus • male • bone mineral density • prolactin • testosterone.

Lupus, Vol. 5, No. 6, 623-626 (1996)
DOI: 10.1177/096120339600500612


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. Lilleby Review: Bone status in juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 580 - 586. [Abstract] [PDF]

				D Schapira, A Kabala, B Raz, and E Israeli Osteoporosis in murine systemic lupus erythematosus - a laboratory model Lupus, June 1, 2001; 10(6): 431 - 438. [Abstract] [PDF]